Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 3 » Issue 1

End of life care in chronic obstructive pulmonary disease: in search of a good death

Authors Anna Spathis, Sara Booth

Published Date March 2008 Volume 2008:3(1) Pages 11—29

DOI http://dx.doi.org/10.2147/COPD.S698

Published 18 March 2008

Anna Spathis, Sara Booth

Palliative Care Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, UK

Abstract: Chronic obstructive pulmonary disease (COPD) is an incurable, progressive illness that is the fourth commonest cause of death worldwide. Death tends to occur after a prolonged functional decline associated with uncontrolled symptoms, emotional distress and social isolation. There is increasing evidence that the end of life needs of those with advanced COPD are not being met by existing services. Many barriers hinder the provision of good end of life care in COPD, including the inherent difficulties in determining prognosis. This review provides an evidence-based approach to overcoming these barriers, summarising current evidence and highlighting areas for future research. Topics include end of life needs, symptom control, advance care planning, and service development to improve the quality of end of life care.

Keywords: chronic obstructive pulmonary disease (MeSH), palliative care (MeSH), dyspnoea (MeSH), advance care planning (MeSH)

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Lebrikizumab in the personalized management of asthma

Thomson NC, Patel M, Smith AD

Biologics: Targets and Therapy 2012, 6:329-335

Published Date: 14 September 2012

Concentration-dependent effects of fullerenol on cultured hippocampal neuron viability

Zha YY, Yang B, Tang ML, Guo QC, Chen JT, Wen LP, Wang M

International Journal of Nanomedicine 2012, 7:3099-3109

Published Date: 29 June 2012

Antibiofilm surface functionalization of catheters by magnesium fluoride nanoparticles

Lellouche J, Friedman A, Lahmi R, Gedanken A, Banin E

International Journal of Nanomedicine 2012, 7:1175-1188

Published Date: 1 March 2012

Enhanced solubility and functionality of valrubicin (AD-32) against cancer cells upon encapsulation into biocompatible nanoparticles

Sabnis N, Nair M, Israel M, McConathy WJ, Lacko AG

International Journal of Nanomedicine 2012, 7:975-983

Published Date: 22 February 2012

Antipsychotic adherence, switching, and health care service utilization among Medicaid recipients with schizophrenia

Douglas L Noordsy, Glenn A Phillips, Daniel E Ball, et al

Patient Preference and Adherence 2010, 4:263-271

Published Date: 20 July 2010

Daunorubicin-loaded magnetic nanoparticles of Fe3O4 overcome multidrug resistance and induce apoptosis of K562-n/VCR cells in vivo

Bao-an Chen, Bin-bin Lai, Jian Cheng, et al

International Journal of Nanomedicine 2009, 4:201-208

Published Date: 23 September 2009

A genetic study of the NOS3 gene for ischemic stroke in a Chinese population

Danhua Du, Peng Gao, Linsen Hu, Yumei Yang, Feng Wang, et al

International Journal of General Medicine 2008, 1:65-68

Published Date: 28 September 2008